Net Income

Response Pharmaceuticals unveils promising data on RDX-002, a first-in-class drug aimed at preventing a severe side effect of essential mental health drugs.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.

As data breach litigation skyrockets, specialist law firm Mullen Coughlin bolsters its defense with the strategic hire of 30-year trial veteran MaryEllen Conroy.

Amidst a quarterly loss, Coincheck inks a major deal with telco giant KDDI and expands into institutional ETFs, betting big on a diversified future.

A Belgian firm's new biologic gel for diabetic foot ulcers gets a key FDA green light, offering hope against a leading cause of amputations.

A new optical switch from University of Arizona research is 1,000x faster and uses 99.9% less energy, promising a sustainable future for data centers and AI.

A new report reveals burnout and declining morale are pushing travel nurses out, forcing hospitals to rethink retention beyond just competitive pay.

Amid a surging lithium market, Lithium Argentina posts stellar Q1 results, using its operational prowess to fund ambitious expansion projects in Argentina.

With demand for blood and plasma soaring, Canadian Blood Services is betting on national pride to solve a critical shortage. But can a new campaign work?

Retailer Rural King is leveraging its free popcorn tradition into a national series, kicking off with champion Joey Chestnut in Terre Haute this Memorial Day.

Despite a net loss, Ampco-Pittsburgh posts record results in one segment and a growing backlog, signaling a potential turnaround for the rest of 2026.

Event management firm Dreamland is moving into AI, partnering to build an intelligent image library. Can it revolutionize media management or is it a risky bet?

The sale of The Blake at Tyler to a REIT highlights a national trend: intense investor demand for upscale, resort-style senior living communities.

Portuguese giant Sonae leverages a diverse portfolio and key acquisitions to achieve unprecedented financial growth and a 76% share price surge in 2025.

The medtech firm reports a 19% revenue surge and a return to profitability, validating its new pure-play strategy focused on the surgical market.

In a sector obsessed with user growth, the Philippines' first standalone digital bank achieves profitability by focusing on what matters: lending.

Amid a $10M loss and a major foreclosure, Bioceres slashes costs and bets on a strategic pivot. Can the ag-tech firm navigate its financial storm?

As Fabrinet preps for a key J.P. Morgan conference, record revenues clash with supply chain woes, putting its role in the AI revolution under a microscope.

Amidst fierce regulatory pressure, Optum Rx is ditching traditional pricing for a transparent, fee-based system. Will competitors follow suit?

Cadre Holdings reports a record $355M backlog and higher sales, yet profits fall sharply due to acquisition costs, signaling a high-stakes growth strategy.